D018380ProceduresE02.095.147.500.500.500E04.936.225.687.5001408780.592702Hematopoietic Stem Cell TransplantationFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMedicine-Infectious DiseasesEricPamerEric Pamer41.7886000000000087.598699999999993819Pamer, EricProfessorKoenVan BesienKoen Van Besien0.000000000000000.000000000000002944Van Besien, KoenPROFESSOR22.42170.0138058140research area of0.9914970.0333107650subject area forMedicine-Hematology and OncologyMariamNawasMariam Nawas41.7886000000000087.598699999999994095Nawas, MariamAssistant Professorhttps://pamerlab.uchicago.eduPamer Lab websitehttp://dfi.uchicago.eduDuchossois Family Institute37463058Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan DClinical cancer research : an official journal of the American Association for Cancer ResearchRandomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 12 01; 29(23):4784-4796.Clin Cancer Res2023-12-01T00:00:002023Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.MedicineUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.Professor37801340Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller GLeukemia & lymphomaMeasurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77.Leuk Lymphoma2024-01-10T00:00:002024Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.37913908Williams LS, Williams KM, Gillis N, Bolton K, Damm F, Deuitch NT, Farhadfar N, Gergis U, Keel SB, Michelis FV, Panch SR, Porter CC, Sucheston-Campbell L, Tamari R, Stefanski HE, Godley LA, Lai CTransplantation and cellular therapyDonor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2024 Mar; 30(3):255-267.Transplant Cell Ther2023-10-31T00:00:002023Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.38096805Nawas MT, Kosuri SBlood advancesUtility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML. Blood Adv. 2024 02 13; 8(3):553-561.Blood Adv2024-02-13T00:00:002024Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.38302122Kaviany S, Barnawi Z, LaBelle JPediatric annalsCurative Therapies for Sickle Cell Disease. Pediatr Ann. 2024 Feb; 53(2):e56-e61.Pediatr Ann2024-02-01T00:00:002024Curative Therapies for Sickle Cell Disease.true1PROFESSORPROFESSORtrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor1010Michael R.BishopMichael R. Bishop0.000000000000000.000000000000002689Bishop, Michael R.Professor